6 completed, 5 recruiting, 1 active not recruiting, 1 unknown. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 6, Recruiting 5, Active not recruiting 1, Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow letermovir: new trials by email Literature Review of letermovir trials Research Report on letermovir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant Letermovir, Valganciclovir - CMV Viremia, Heart Transplant Infection | Phase 2 / Phase 3 | Recruiting | Columbia University | 150 | 2025-09-12 | 2026-10-02 |
| Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections Letermovir, Valganciclovir, Letermovir placebo - Cytomegalovirus Infection | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 80 | 2024-08-14 | 2026-01-02 |
| Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients Letermovir - Cytomegalovirus Infections, Kidney Transplant Infection | Phase 3 | Recruiting | University of Wisconsin, Madison | 90 | 2024-08-08 | 2026-06-11 |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients Biospecimen Collection, Letermovir - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 3 | Recruiting | Children's Oncology Group | 105 | 2024-07-11 | 2026-10-06 |
| CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT Letermovir - Hematologic Malignancy | Phase 3 | Active not recruiting | Ruijin Hospital | 250 | 2024-07-01 | 2025-12-15 |
| Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection Letermovir 480 MG, Ganciclovir - CMV Infection | Phase 3 | Unknown | Hospital do Rim e Hipertensão | 100 | 2024-05-05 | 2024-04-02 |
| Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir Letermovir, Valacyclovir - Pregnant Women, CMV Infected Fetuses | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 46 | 2023-10-20 | 2026-03-31 |
| De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients Letermovir 480 mg once daily, Historical/Control - Kidney Transplant; Complications, CMV | Phase 3 | Completed | Virginia Commonwealth University | 30 | 2023-09-25 | 2026-09-23 |
| A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045) Letermovir - Cytomegalovirus Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 120 | 2023-03-24 | 2025-03-25 |
| MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) Letermovir tablet, Letermovir IV - Cytomegalovirus Infection, Cytomegalovirus Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 22 | 2019-12-27 | 2024-08-21 |
| Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) Letermovir, Placebo - Cytomegalovirus Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 220 | 2019-06-21 | 2024-08-22 |
| Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) Letermovir, Valganciclovir, Acyclovir (ACV) - CMV Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 601 | 2018-05-03 | 2023-07-28 |
| Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) Letermovir, Placebo - Prevention of CMV Infection or Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 570 | 2014-06-06 | 2019-09-11 |
Cytomegalovirus Infections (6) · Hematologic Neoplasms (2) · Disease (1) · Rejection, Psychology (1)
Merck Sharp & Dohme LLC (5) · Assistance Publique - Hôpitaux de Paris (2) · Children's Oncology Group (1) · Columbia University (1) · Hospital do Rim e Hipertensão (1) · Ruijin Hospital (1) · University of Wisconsin, Madison (1) · Virginia Commonwealth University (1)
United States (6) · France (4) · China (2) · Germany (2) · Italy (2) · Japan (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Colombia (1) · Hungary (1) · Mexico (1)
Caitlin W Elgarten (1) · Gaurav Gupta, MD (1) · Helio Tedesco (1) · Sandesh Parajuli, MBBS (1)
PMID 27682069, PMID 29211658, PMID 29319768, PMID 30137245, PMID 31081566, PMID 31179485, PMID 31978003, PMID 32134486, PMID 33440077, PMID 34674258, PMID 36464218, PMID 37279999, PMID 38142695, PMID 38615067, PMID 38700045, PMID 38853607, PMID 41321121, PMID 42639594
2017 (1), 2018 (1), 2023 (1), U24CA196173 (1), UG1CA189955 (1)